ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $235,000 | -65.2% | 2,002 | -60.1% | 0.01% | -66.7% |
| Q4 2021 | $675,000 | -69.4% | 5,019 | -70.1% | 0.02% | -69.4% |
| Q2 2021 | $2,209,000 | +145.4% | 16,793 | +140.4% | 0.05% | +145.0% |
| Q1 2021 | $900,000 | -10.4% | 6,984 | +16.1% | 0.02% | +5.3% |
| Q4 2020 | $1,004,000 | -36.0% | 6,018 | -40.8% | 0.02% | -54.8% |
| Q3 2020 | $1,568,000 | +5.5% | 10,163 | +1.1% | 0.04% | -2.3% |
| Q2 2020 | $1,486,000 | +174.2% | 10,049 | +108.7% | 0.04% | +104.8% |
| Q1 2020 | $542,000 | -22.1% | 4,815 | -3.7% | 0.02% | +90.9% |
| Q4 2019 | $696,000 | +82.2% | 5,000 | -77.3% | 0.01% | -35.3% |
| Q1 2015 | $382,000 | – | 22,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |